E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10020469 |
E.1.2 | Term | Huntington's chorea |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- To assess the efficacy of AFQ056 on the severity of chorea in Huntington’s disease patients in clinical stages I-III on day 28, using the Unified Huntington’s Disease Rating Scale (UHDRS) Maximal Chorea score and* the orientation index from the quantitative grip force motor assessment.
*Both co-primary objectives will be assessed, but achievement of one OR the other co-primary endpoint is sufficient to achieve PoC.
- To assess the safety and tolerability of multiple titrated doses of AFQ056 in Huntington’s disease patients in clinical stages I-III.
|
|
E.2.2 | Secondary objectives of the trial |
To assess the potential effect of multiple titrated doses of AFQ056 on the motor, cognitive, behavioral and functional assessments using the Unified Huntington’s Disease Rating Scale (UHDRS).
To assess the potential effect of multiple titrated doses of AFQ056 on Functional and Quality of Life scales, neuropsychiatric assessments and cognitive assessments in Huntington’s Disease patients in clinical stages I-III
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male and female patients between 30 and 85 years of age (both inclusive).
2. Patients diagnosed with Huntington’s Disease based on DNA testing (polyQ ≥36).
3. Patients with a UHDRS maximal chorea score of >10.
4. Patients treated with neuroleptics, antidepressants, and/or benzodiazepines are allowed to enter the study provided that they are on a stable regimen for at least 4 weeks prior to randomization.
5. Female subjects must be without childbearing potential (post-menopausal or surgically sterilized). Postmenopausal females must have had no regular menstrual bleeding for at least one (1) year prior to initial dosing. Menopause will be confirmed by a plasma FSH level of >40 IU/L at screening. For post-menopausal females treated with estrogen replacement therapy, FSH level is artificially lowered <40 IU/L. Estradiol and LH measurements need to be performed to confirm reason for low FSH value. Female subjects who report surgical sterilization must have had the procedure at least six (6) months prior to initial dosing. Surgical sterilization procedures should be supported with clinical documentation made available to the sponsor and noted in the Relevant Medical History / Current Medical Conditions section of the CRF. All female subjects must have negative pregnancy test results at screening and at each baseline.
6. Male patients must be using a double-barrier local contraception for the entire duration of the study, up to the Study Completion visit, and refrain from fathering a child in the three months following the last study drug administration.
7. Subjects must have a BMI in the range of 18-32 to participate in the study.
8. Able to communicate well with the investigator, to understand and comply with the requirements of the study. Understand and sign the written informed consent. |
|
E.4 | Principal exclusion criteria |
1. Patients with marked cognitive impairment (MMSE score of less than 18).
2. Patients with a presence of psychosis, confusional states and/or repeated hallucinations.
3. Patients who participated in an anti-dyskinetic clinical study within 6 months prior to randomization, and/or in any clinical investigation within 4 weeks prior to randomisation, or longer if required by local regulations, and any other limit on participation based on local regulations.
4. Patients using (or have used within four weeks before randomization) concomitant medications that are strong inhibitors of CYP3A4. E.g., ketoconazole, ritonavir, etc.
5. Donation or loss of 400 ml or more of blood within eight (8) weeks prior to initial dosing, or longer if required by local regulation.
6. Significant illness (other than Huntington’s Disease) within two (2) weeks prior to initial dosing.
7. A past medical history of clinically significant ECG abnormalities or a family history grandparents, parents and siblings) of a prolonged QT-interval syndrome.
8. Recent (within the last three years) and/or recurrent history of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated).
9. History of multiple and recurring allergies or allergy to the investigational compound/compound class being used in this study.
10. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the study. The Investigator should make this determination in consideration of the subject’s medical history and/or clinical laboratory test results at screening and baseline.
11. Total WBC count which falls outside the normal ranges of the laboratory at screening, and deemed of clinical relevance by the investigator.
12. History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result.
13. A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.
14. History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such abuse as indicated by the laboratory assays conducted during the screening and/or at baseline.
15. Subjects who have been committed to an institution by way of an official or judicial order will be excluded from participation to the study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary analyses is based on the maximal Chorea rating of the UHDRS motor component at the end of the maintenance treatment phase on day 28 after the morning dose. This endpoint considers the face, mouth, trunk and 4 limbs rating each on a scale 0-4, where higher values represent a higher burden of disease. The sum score therefore ranges from 0 to 28. The absolute changes from baseline will be used as the outcome measures. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 8 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 0 |